» Articles » PMID: 30058426

Decreased Apolipoprotein A4 and Increased Complement Component 3 As Potential Markers for Papillary Thyroid Carcinoma: A Proteomic Study

Overview
Specialties Biochemistry
Oncology
Date 2018 Jul 31
PMID 30058426
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background:: Thyroid carcinomas have comprised the fastest rising incidence of cancer in the past decade. Currently, the diagnosis of thyroid tumors is performed by the fine-needle aspiration biopsy (FNAB) method, which still holds some challenges and limitations, mostly in discriminating malignant and benign lesions. Therefore, the development of molecular markers to distinguish between these lesion types are in progress.

Methods:: A 2D-PAGE separation of proteins was performed followed by tandem mass spectrometry with the aim of discovering potential serum protein markers for papillary thyroid carcinoma and multinodular goiter. Protein-protein interaction network analysis revealed the most important pathways involved in the progression of papillary thyroid cancer. The enzyme-linked immunosorbent assay method was used to confirm a part of the results.

Results:: The significantly altered proteins included C3, C4A, GC, HP, TTR, APOA4, APOH, ORM2, KRT10, AHSG, IGKV3-20, and IGKC. We also confirmed that increased complement component 3 and decreased apolipoprotein A4 occurred in papillary thyroid cancer. Network investigations demonstrated that complement activation cascades and PPAR signaling might play a role in the pathogenesis of thyroid cancer.

Conclusion:: The results demonstrated that serum proteomics could serve as a viable method for proposing novel potential markers for thyroid tumors. Surely, further research must be performed in larger cohorts to validate the results.

Citing Articles

Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020.

Samimi H, Shirzad N, Sajjadi-Jazi S, Heshmat R, Amoli M, Mohajeri-Tehrani M J Diabetes Metab Disord. 2024; 23(2):1-9.

PMID: 39610531 PMC: 11599522. DOI: 10.1007/s40200-020-00702-1.


Omics experiments in Iran, a review in endocrine and metabolism disorders studies.

Hosseinkhani S, Arjmand B, Bandarian F, Aazami H, Hadizadeh N, Najjar N J Diabetes Metab Disord. 2024; 23(2):1539-1544.

PMID: 39610495 PMC: 11599483. DOI: 10.1007/s40200-021-00727-0.


Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study.

Kollerits B, Gruber S, Steinbrenner I, Schwaiger J, Weissensteiner H, Schonherr S BMC Cancer. 2024; 24(1):320.

PMID: 38454416 PMC: 10921727. DOI: 10.1186/s12885-024-12053-8.


Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review).

Yang S, Zhu G, He R, Fang D, Feng J Oncol Lett. 2023; 26(3):396.

PMID: 37600346 PMC: 10433702. DOI: 10.3892/ol.2023.13982.


Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer.

Ye G, Zhang X, Li M, Lin Z, Xu Y, Dong H BMC Cancer. 2023; 23(1):412.

PMID: 37158852 PMC: 10165821. DOI: 10.1186/s12885-023-10839-w.